Details of the Drug

General Information of Drug (ID: DMEBQAO)

Drug Name
Lumasiran
Indication
Disease Entry ICD 11 Status REF
Hyperoxaluria 5C51.2 Approved [1]
ATC Code
A16AX18: Lumasiran
A16AX: Various alimentary tract and metabolism products
A16A: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A: ALIMENTARY TRACT AND METABOLISM
Drug Type
Small interfering RNA
Sequence
>Subunit 1
GACUUUCAUCCUGGAAAUAUAX
>Subunit 2
UAUAUUUCCAGGAUGAAAGUCCA
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 7400 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 529 mcg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4 h [2]
Clearance
The renal clearance of drug is 2.0-3.4 L/h [2]
Elimination
7-26% of a dose of lumasiran is recovered in the urine as the unmetabolized parent compound [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.2 hours [2]
Metabolism
The drug is metabolized via the endonucleases and exonucleases [2]
Vd
The volume of distribution (Vd) of drug is 4.9 L [2]
Cross-matching ID
UNII
RZT8C352O1
DrugBank ID
DB15935
TTD ID
DD1GK8

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HAO1 messenger RNA (HAO1 mRNA) TTS58YO HAOX1_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 EMA Summary of Product Characteristics: Oxlumo (Lumasiran) Subcutaneous Injection